New hope for hard-to-treat myeloma with targeted drug combo
NCT ID NCT04126200
First seen Nov 06, 2025 · Last updated May 08, 2026 · Updated 21 times
Summary
This study tests a drug called belantamab mafodotin, alone or with other cancer drugs, in people with multiple myeloma that has come back or stopped responding to treatment. About 208 adults who have already tried at least three other treatments will take part. The goal is to see if these combinations can better control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Atlanta, Georgia, 30322, United States
-
GSK Investigational Site
Indianapolis, Indiana, 46202, United States
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Grand Rapids, Michigan, 49546, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Porto Alegre, 90110-270, Brazil
-
GSK Investigational Site
Salvador, 41253-190, Brazil
-
GSK Investigational Site
São Paulo, 04537-080, Brazil
-
GSK Investigational Site
Vancouver, British Columbia, V5Z1M9, Canada
-
GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
Lille, 59037, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Frankfurt, 60590, Germany
-
GSK Investigational Site
Hamburg, 20246, Germany
-
GSK Investigational Site
Kiel, 24105, Germany
-
GSK Investigational Site
Leipzig, 04103, Germany
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Mexico City, 01330, Mexico
-
GSK Investigational Site
Leeuwarden, 8934 AD, Netherlands
-
GSK Investigational Site
Utrecht, 3584 CX, Netherlands
-
GSK Investigational Site
Oslo, 0450, Norway
-
GSK Investigational Site
Gdansk, 80-214, Poland
-
GSK Investigational Site
Katowice, 40-519, Poland
-
GSK Investigational Site
Lodz, 93-513, Poland
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Incheon, 21565, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 06351, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Badalona, 08916, Spain
-
GSK Investigational Site
Madrid, 28027, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
PamplonaNavarra, 31008, Spain
-
GSK Investigational Site
Pozuelo de AlarcOn Madr, 28223, Spain
-
GSK Investigational Site
Falun, SE-791 82, Sweden
-
GSK Investigational Site
Stockholm, SE-141 86, Sweden
Conditions
Explore the condition pages connected to this study.